CEDAR KNOLLS, NJ--(Marketwire - Oct 9, 2012) - MYOS Corporation (OTCBB: MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, announced today that its premiere distributor, MHP, recently launched MYO-X™, and it is now available through the website of nutrition retail powerhouse, GNC. MYO-X contains MYOS' breakthrough MYO-T12™, the world's first clinically proven myostatin inhibitor designed to build lean muscle mass and improve strength and endurance. The company anticipates that its products will be distributed throughout GNC stores in the very near future.
Peter Levy, Chief Operating Officer of MYOS, said, "We believe GNC will bring MYO-X to a wider range of consumers, and will enhance our product's availability by associating it with a widely respected retailer of health and nutrition products in the world."
Myostatin is a natural regulatory protein that blocks muscle growth and impedes repair. MYO-X temporarily inhibits production of this protein, allowing for more rapid muscle growth and recovery from exercise or injury. This makes MYO-X a highly desirable product for health aficionados and athletes as an aid to building muscle, and a perfect fit for GNC stores.
GNC has more than 4,800 retail locations throughout the United States, including more than 1,000 franchises and more than 1,200 Rite-Aid store-within-store locations.
About MYOS Corporation
MYOS Corporation is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance. MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of MYO-X, the ability to generate the forecasted revenue stream and cash flow from sales of MYO-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.